This course has expired. View available courses.
Infectious Disease
Bivalent COVID-19 Boosters – What You Need to Know to Educate and Protect Your Patients
Vaccines have made a significant difference in the risk of severe outcomes associated with COVID-19. Over the last 2.5 years, new variants have occurred that have led to changes in transmissibility and outcomes compared to the original SARS-CoV-2 virus. The omicron variant has significant mutations that are associated with an increase in transmissibility and higher risk of immune escape from current vaccines. The recently approved bivalent mRNA vaccines offer a different strategy to address the omicron variant.
DURATION
1 hr
PROFESSION
Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2023-09-28
Vaccines have made a significant difference in the risk of severe outcomes associated with COVID-19. Over the last 2.5 years, new variants have occurred that have led to changes in transmissibility and outcomes compared to the original SARS-CoV-2 virus. The omicron variant has significant mutations that are associated with an increase in transmissibility and higher risk of immune escape from current vaccines. The recently approved bivalent mRNA vaccines offer a different strategy to address the omicron variant. In this webinar, experts will review the key clinical considerations for this new booster so healthcare professionals can address:
- Why the bivalent booster was introduced
- How it compares to current boosters in terms of immune response
- The safety of this new vaccine option
- Common patient questions regarding the bivalent booster option
This program has received funding from Moderna.
Faculty
Peter Lin, MD, CCFP
David Strain, MBChB, MD, FRCP
Vivien Brown, MDCM, CCFP, FCFP, NCMP
Allison McGeer, MSc, MD, FRCPC
Learning objectives
Upon completion of this continuing education video participants will be better able to:
- Discuss the efficacy of current mRNA boosters in preventing symptomatic COVID-19 and its severe outcomes
- List reasons that the omicron variant requires a different booster strategy to protect patients
- Describe the immune response and safety of bivalent boosters compared to current mRNA COVID-19 boosters
- Address common patient questions and concerns regarding the new bivalent COVID-19 boosters
#
of credits: 0
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist
Profession
0
# of credits
Learning Objectives
Upon completion of this continuing education video participants will be better able to:
- Discuss the efficacy of current mRNA boosters in preventing symptomatic COVID-19 and its severe outcomes
- List reasons that the omicron variant requires a different booster strategy to protect patients
- Describe the immune response and safety of bivalent boosters compared to current mRNA COVID-19 boosters
- Address common patient questions and concerns regarding the new bivalent COVID-19 boosters
Unaccredited
ACCREDITATION
Infectious Disease
Learning Category
General
Topic
0
Price
2023-09-28
Expiry Date
CAN-eng
Region/Language
Course Description
Vaccines have made a significant difference in the risk of severe outcomes associated with COVID-19. Over the last 2.5 years, new variants have occurred that have led to changes in transmissibility and outcomes compared to the original SARS-CoV-2 virus. The omicron variant has significant mutations that are associated with an increase in transmissibility and higher risk of immune escape from current vaccines. The recently approved bivalent mRNA vaccines offer a different strategy to address the omicron variant. In this webinar, experts will review the key clinical considerations for this new booster so healthcare professionals can address:
- Why the bivalent booster was introduced
- How it compares to current boosters in terms of immune response
- The safety of this new vaccine option
- Common patient questions regarding the bivalent booster option
This program has received funding from Moderna.
Faculty
Peter Lin, MD, CCFP
David Strain, MBChB, MD, FRCP
Vivien Brown, MDCM, CCFP, FCFP, NCMP
Allison McGeer, MSc, MD, FRCPC
Accreditation
1 hr
Duration
0
Price
0
# of credits
